Barriers to the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
- PMID: 39836619
- PMCID: PMC11749880
- DOI: 10.1210/clinem/dgae710
Barriers to the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Abstract
Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare genetic condition that requires lifelong management from birth. Individuals with CAH and their families often face structural barriers to obtaining comprehensive care and treatment, including limited access to appropriate newborn screening, comprehensive care centers, and medications. Social and cultural barriers to care may include stigmatization, discrimination, and adverse medical experiences. At the individual and family level, comprehensive care may be affected by education, finances, health-care coverage, geographic location, and lack of social supports. These barriers are often further magnified for individuals living in underresourced countries. Inadequate access to comprehensive care and medications increases the risk of life-threatening adrenal crisis and disease-related comorbidities. This review article examines the current structural, sociocultural, and individual barriers that individuals with CAH and their families may face when managing their condition throughout their lifetime.
Keywords: access; barrier; congenital adrenal hyperplasia; education; screening; stigma.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.
Figures
Similar articles
-
Life With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Challenges and Burdens.J Clin Endocrinol Metab. 2025 Jan 21;110(Supplement_1):S56-S66. doi: 10.1210/clinem/dgae728. J Clin Endocrinol Metab. 2025. PMID: 39836616 Free PMC article.
-
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency - the next disease included in the neonatal screening program in Poland.Dev Period Med. 2018;22(2):197-200. doi: 10.34763/devperiodmed.20182202.197200. Dev Period Med. 2018. PMID: 30056407 Free PMC article. Review.
-
Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.J Clin Endocrinol Metab. 2025 Jan 21;110(Supplement_1):S13-S24. doi: 10.1210/clinem/dgae563. J Clin Endocrinol Metab. 2025. PMID: 39836622 Free PMC article. Review.
-
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.J Spec Pediatr Nurs. 2005 Jul-Sep;10(3):104-14. doi: 10.1111/j.1744-6155.2005.00022.x. J Spec Pediatr Nurs. 2005. PMID: 16083430 Review.
-
Congenital adrenal hyperplasia: issues in diagnosis and treatment in children.Indian J Pediatr. 2014 Feb;81(2):178-85. doi: 10.1007/s12098-013-1280-8. Epub 2013 Nov 20. Indian J Pediatr. 2014. PMID: 24254335 Review.
Cited by
-
Growth Assessment and Nutritional Status in Children with Congenital Adrenal Hyperplasia-A Cross-Sectional Study from a Vietnamese Tertiary Pediatric Center.Diagnostics (Basel). 2025 Jun 16;15(12):1534. doi: 10.3390/diagnostics15121534. Diagnostics (Basel). 2025. PMID: 40564853 Free PMC article.
-
Life With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: Challenges and Burdens.J Clin Endocrinol Metab. 2025 Jan 21;110(Supplement_1):S56-S66. doi: 10.1210/clinem/dgae728. J Clin Endocrinol Metab. 2025. PMID: 39836616 Free PMC article.
References
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical